01:41 EDT 20th September 2017 | BioPortfolio

Located in France, close to the biotech heart of Geneva, the CIPF is a part of Pierre FABRE Laboratories (over 9000 people in France and overseas).
Created in 1990, our Research Centre - 100 collaborators - is dedicated to the discovery, development and production of antibody-based molecules to treat cancer. Combining multiple research expertise in experimental oncology, genetic engineering, molecular and cellular biology, and biochemistry, together with a sound know-how in antibody humanization, cellular imaging, molecular modelling and bioinformatics.

In addition, the CIPF possesses an Industrial Pilot plant dedicated to process development and production of recombinant molecules of therapeutic interest.


5,avenue Napoléon III
St Julien en
Genevois Cedex,
BP 497, 74164


Phone: 33
Fax: 33

News Articles [574 Associated News Articles listed on BioPortfolio]

Pierre Fabre to commercialize Aprotecol in Italy

Spain-based Noventure and the Italian subsidiary of France’s Pierre Fabre have entered into an agreement…

Pierre Fabre sets sights on bigger I-O business

Privately-held Pierre Fabre Pharmaceuticals is buying immuno-oncological candidates from Igenica Biotherapeutics,…

Pierre Fabre Acquires Ingenica Immuno-Oncology Assets

Pierre Fabre said today it has agreed to acquire “several” cancer immunotherapies from Igenica Biotherapeutics for an undisclosed price, in a deal designed to strengthen the buyer’s oncology pip...

Pierre Fabre Acquires Igenica Immuno-Oncology Assets

Pierre Fabre said today it has agreed to acquire “several” cancer immunotherapies from Igenica Biotherapeutics for an undisclosed price, in a deal designed to strengthen the buyer’s oncology pip...

Pierre Fabre Buys Igenica Immuno-oncology Assets

Deal reinforces Pierre Fabre’s pipeline in oncology, its primary R&D focus area

Pierre Fabre to buy Igenica Biotherapeutics’ assets for treating cancer patients

French private pharmaceutical group Pierre Fabre has signed a new definitive purchase agreement to acquire several assets from US biotechnology company Igenica Biotherapeutics.

Pierre Fabre secures Italian distribution rights for Noventure's Aprotecol

Noventure has allied with Pierre Fabre Pharma Italy in a partnership which will see the latter distribute the Spanish start-up’s paediatric intestinal treatment Aprotecol in Italy. read more

Pierre Fabre acquires immuno-oncology assets from Igenica

Pierre Fabre Group acquired certain immuno-oncology assets from Igenica Biotherapeutics Inc. Specific projects and financial details were not disclosed.

PubMed Articles [398 Associated PubMed Articles listed on BioPortfolio]

Ameloblastic Fibro-Odontoma of the Maxilla in a Pierre-Robin Sequence Patient.

Pierre Robin sequence (PRS) is a rare disorder classically observed as a triad of features including micrognathia, glossoptosis, and upper airway obstruction. It is associated with a syndrome in about...

Stromal networking: cellular connections in the germinal centre.

Secondary lymphoid organs are organized into distinct zones, governed by different types of mesenchymal stromal cells. These stromal cell subsets are critical for the generation of protective humoral ...

Spectrum of biopsy proven renal disease in South Asian children: Two decades at a tropical tertiary care centre.

We report findings from a large single centre paediatric renal biopsy cohort in South Asia.


Integra® dermal replacement has a wide spectrum of use both in burn medicine as well as in reconstructive plastic surgery and traumatology. Since 2002, it has been a part of surgical treatment of pat...

The practice pattern of anticoagulation prophylaxis for patients undergoing total hip replacement in a major orthopaedic centre; a retrospective review.

In a major centre for orthopaedic surgery, we retrospectively analysed 1,469 patients who underwent elective hip replacement since 2010. All patients but 2 received anticoagulation postoperatively and...

Clinical Trials [849 Associated Clinical Trials listed on BioPortfolio]

Impact of Phonatory and Facial Morphology Disorders, on the Quality of Life of Adolescents With Pierre Robin Sequence

The study team has made the hypothesis that the intensity of the phonatory disorders (rhinolalia), and of the maxillo-mandibular growth anomalies (facial morphology), may have negative eff...

Early Treatment Outcomes in Pierre-Robin-Like Phenotype

In a longitudinal cohort study, we want to assess the effect of the pre-epiglottic baton plate, the main treatment approach currently used in Germany for Pierre-Robin-Like phenotype, on up...

A Multi-Centre Clinical Study in Chronic Spinal Cord Injury Patients

To establish a solid foundation, e.g. network and a coordinating centre for testing new SCI therapies in forthcoming randomized controlled multi-centre clinical trials following internatio...

Evaluating an Intervention to Increase Use of Call Centre Support for Self-managed Medical Abortion

Self-management of medical abortion (MA) pills purchased from pharmacies is considered to be one of the reasons behind falling morbidity and mortality from unsafe abortion in recent years....

Comparing Nutritional Status of In-centre Nocturnal Hemodialysis Patients to Conventional Hemodialysis Patients

Although hemodialysis is life-saving, unfortunately, people on dialysis often have declining health, quality of life as well as poor nutritional status. Hemodialysis patients must follow a...

Companies [368 Associated Companies listed on BioPortfolio]

Pierre Fabre SA

Pierre Fabre group, France's second biggest independent pharmaceutical laboratory, achieved a turnover of 1.75 billion euros in 2008. Approximatively 10,000 people including 1,400 in the research ...


Located in France, close to the biotech heart of Geneva, the CIPF is a part of Pierre FABRE Laboratories (over 9000 people in France and overseas). Created in 1990, our Research Centre - 100 collabor...

Groupe Pierre Fabre

The Pierre Fabre Group, the second largest independent French pharmaceutical company and leader in the field of in-pharmacy dermo-cosmetics, employs about 10,000 people worldwide, including 1,400 ...

Laboratoires Pierre Fabre S A



Supporting Food and Health industriesA specialist in stainless steel products and a designer and manufacturer of process vessels integrating sophisticated and innovative features in agitation, mixing,...

More Information about "CENTRE D’IMMUNOLOGIE PIERRE FABRE" on BioPortfolio

We have published hundreds of CENTRE D’IMMUNOLOGIE PIERRE FABRE news stories on BioPortfolio along with dozens of CENTRE D’IMMUNOLOGIE PIERRE FABRE Clinical Trials and PubMed Articles about CENTRE D’IMMUNOLOGIE PIERRE FABRE for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of CENTRE D’IMMUNOLOGIE PIERRE FABRE Companies in our database. You can also find out about relevant CENTRE D’IMMUNOLOGIE PIERRE FABRE Drugs and Medications on this site too.

Quick Search

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Corporate Database Quicklinks

Searches Linking to this Company Record